Adjuvant atezolizumab in NSCLC

IMPOWER 010

Background:

Since the LACE meta-analysis showed benefit of adjuvant chemotherapy in early-stage (Stage IB-IIIA) non-small cell lung cancer, there hasn’t been a strategy that showed clear benefit to improving outcomes. In the LACE meta-analysis, the benefit was quite modest at 4-5% compared to observation. Strategies such as addition of bevacizumab faile…